Astrazeneca (AZN) Current Deferred Revenue (2018 - 2020)

Astrazeneca's Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $12.0 million for Q4 2020.

• In Q4 2020, Current Deferred Revenue fell 57.14% year-over-year to $12.0 million; the TTM figure through Dec 2020 stood at $12.0 million (down 57.14% YoY), while the FY2020 annual figure was $12.0 million, down 57.14% from the prior year.
• Current Deferred Revenue was $12.0 million for Q4 2020 at Astrazeneca, down from $28.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $92.0 million in Q4 2018 to a low of $12.0 million in Q4 2020.
• Historically, Current Deferred Revenue has averaged $44.0 million across 3 years, with a median of $28.0 million in 2019.
• The sharpest annual moves came in 2019 and 2020: Current Deferred Revenue slumped 69.57% in 2019, then plunged 57.14% in 2020.
• A 3-year view of Current Deferred Revenue shows it stood at $92.0 million in 2018, then plunged by 69.57% to $28.0 million in 2019, then slumped by 57.14% to $12.0 million in 2020.
• The last three Current Deferred Revenue figures came in at $12.0 million (Q4 2020), $28.0 million (Q4 2019), and $92.0 million (Q4 2018), per Business Quant data.